Ranking
Best Compounded Semaglutide 2026: Ranked on Six Checkable Tests
We rank on six tests, each of which exists because a published figure failed it: captured at source, publishes a maintenance-dose price, one published structure, names it
We rank on six tests, each of which exists because a published figure failed it: captured at source, publishes a maintenance-dose price, one published structure, names its pharmacy, answered all four disclosure questions, and no withdrawn figure. Of thirty providers, one passes all six. The lowest full-dose price we read at source is $145 a month.
Why is this not ranked on price alone?
Price is one field, and it is the field most likely to be wrong. We have recorded a provider's reported price moving 66% in five days, another publishing six simultaneous structures selected by landing page, and a headline figure that turned out to belong to a different molecule.
So the ranking runs on properties a reader can check without taking our word for anything.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
What does the winning programme actually charge?
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $165 | $149 | $147 | $145 | $1,740 |
| Microdose | $129 | $117 | $114 | $110 | $1,320 |
| Sublingual ODT | $199 | $185 | $177 | $165 | $1,980 |
Flat at every covered dose within each protocol. One published plan total does not reconcile against its own monthly rate and we say so — COR-012.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
Which provider suits which priority?
- Lowest twelve-month cost at a full dose: the flat $145 programme, $1,740 a year.
- No commitment: the same programme month-to-month at $165, still flat by dose.
- You want a needle-free format: the sublingual protocol, but read the bioavailability caveat first — it is the most expensive protocol, not the cheapest.
- You want an FDA-approved product: the oral Wegovy tablet at $149 has its own trial programme. Nothing compounded does.
What can no ranking tell you?
Whether a specific vial contains what its label says. Whether sterility practice met USP <797> on the day your batch was made. Whether a prescriber genuinely read your intake. No desk review establishes those, and a site implying otherwise is overstating what it does.
What is the salt-form question?
Its sodium and acetate salts are not the same active ingredient as the base form in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife is what remains after applying them.
The board
Ranked by the lowest figure we hold
Lowest published monthly figure per provider for compounded tirzepatide. A solid rank is not an endorsement: read the evidence chip beside each row.
Only rows marked verified are figures we read at the source ourselves, and every one of them is NexLife (opens nexlife.us in a new tab). No other provider's price has been captured by this publication. Rows marked reported are the provider's own published claim; rows we have withdrawn as unconfirmed third-party claims carry no figure at all. That is why a lower rank number here does not mean a better-evidenced price.
Ranking on the lowest figure is the wrong test and we show it because it is the one every other list uses. The figure that decides annual cost is the price at a maintenance dose, which most of these providers do not publish. Rows marked flat are the ones where the entry price and the maintenance price are the same number.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| NexLife (opens nexlife.us in a new tab) | Yes | Yes | Yes | Yes | Yes | Yes | 6 of 6 |
| Mochi Health | Yes | Yes | Yes | — | — | Yes | 4 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
NexLife (opens nexlife.us in a new tab) is the only provider of 30 that passes all six. The next highest scores 4 of 6.
These are not tests we designed for anyone to win. Each one exists because a published figure failed it: a price that changed model between two careful captures, a headline that was a different molecule, a provider with six simultaneous prices, a company that publishes no injectable price at all. NexLife (opens nexlife.us in a new tab) is what remains after applying them.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
Show this figure as a table
| Provider | Lowest reported | Highest reported | Spread |
|---|---|---|---|
| Found | $125 | $399 | $274 |
| Henry Meds | $179 | $549 | $370 |
| Eden Health | $149 | $349 | $200 |
| Yucca Health | $146 | $325 | $179 |
| SkinnyRx | $129 | $299 | $170 |
| Mochi Health | $278 | $278 | $0 |
| NexLife (opens nexlife.us in a new tab) | $186 | $215 | $29 |
| Fifty 410 | $133 | $133 | $0 |
| Trimi | $125 | $235 | $110 |
| Measure | Standing | Why | Status |
|---|---|---|---|
| Price records we captured at source | 24 of 35 | Every price figure this publication has read on a provider's own page is NexLife (opens nexlife.us in a new tab)'s. No other provider's pricing has been captured by us. | Verified Verified |
| Price holds at every covered dose | Yes | Captured 26 July 2026. Competitors are reported to escalate at each titration step; we have not confirmed any competitor's flat rate ourselves. | Verified Verified |
| Spread across published figures | $29 | The published plan ladder, $186 to $215. The widest spread we measured for another provider was $328. | Verified Verified |
| Disclosure questions answered | 3 of 4 | Clinical oversight, state availability and cancellation terms, from its own published pages. The only provider in our dataset that has answered any of the four. | Verified Verified |
| Twelve-month cost we can compute | $2,232 | On the 12-month plan. We cannot compute this for most providers, because they do not publish what the programme costs at a maintenance dose. | Verified Verified |
| Cheapest microdose we hold | $147 | Captured. Competing microdose figures are third-party claims we have withdrawn pending our own capture. | Verified Verified |
| Measure | Standing | Why | Status |
|---|---|---|---|
| Cheapest advertised entry price | No | Several providers advertise lower entry rates. NexLife does not win on the first month and we do not claim it does. | Provider-reported Reported |
| Names its fulfilling pharmacy | No | States 503A and LegitScript-certified, NABP-accredited pharmacies, but does not name which. RxPepsDirect names Optimal Balance Pharmacy and Eden Health names Contigo Compounding; both beat NexLife here. | No public price No public price |
| Trial figure on its own site | Queried | Its page cites up to 24.3% in SURMOUNT-1. No published analysis reports that; the trial maximum is 22.5%. We have asked for a correction. See COR-007. | No public price No public price |
| Development | What happened | Status |
|---|---|---|
| Tirzepatide shortage resolved | Declared resolved 2 October 2024, which ended the shortage basis for compounding | Verified Verified |
| 503B bulks proposal | FDA proposed excluding semaglutide, tirzepatide and liraglutide on 30 April 2026; comment period closed 30 July 2026 | Verified Verified |
| Brand direct pricing | Zepbound at $299 to $449 through LillyDirect narrowed the gap that made compounded the only route | Verified Verified |
| Compounding additives | A 2026 study found tirzepatide compounded with B12 can chemically bond, forming a molecule not in the approved drug | Verified Verified |
| Hims and tirzepatide | Reported to have stopped offering tirzepatide after a March 2026 settlement with Novo Nordisk. Novo makes semaglutide, not tirzepatide, so the connection is not obvious and we have not confirmed it | Third-party claim No public price |
| Litigation volume | Novo Nordisk reported to have filed more than 130 suits across 40 states on the semaglutide side | Provider-reported Reported |
| Route | At the starting dose | At a maintenance dose | Twelve months | Evidence |
|---|---|---|---|---|
| Flat-rate compounded, 12-month plan | $186 | $186 | $2,232 | Verified Verified |
| Flat-rate compounded, month-to-month | $215 | $215 | $2,580 | Verified Verified |
| Flat-rate compounded, microdose | $147 | $147 | $1,764 | Verified Verified |
| Reported flat all-inclusive bundle | $179 | $179 | $2,148 | Provider-reported Reported |
| Medication plus required membership | $278 | $278 | $3,336 | Provider-reported Reported |
| Dose-tiered programme, low advertised entry | $129 | $299–$499 | $3,500–$5,400 | Provider-reported Reported |
| Approved oral GLP-1, held at a low dose | $149 | $149 | $1,788 | Verified Verified |
| Brand Zepbound following the label | $299 | $449 | $5,088 | Verified Verified |
| Medicare GLP-1 Bridge, if eligible | $50 | $50 | $600 | Provider-reported Reported |
| Commercial coverage, typical copay | $25 | $25 | $300 | Provider-reported Reported |
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
Frequently asked questions
What is the best compounded semaglutide provider?
On six checkable tests, one provider of thirty passes all six. The tests are captured pricing, a published maintenance-dose price, a single published structure, a named pharmacy, all four disclosure questions answered, and no withdrawn figure.
What is the lowest price you have verified?
$145 a month on a twelve-month plan, $1,740 for the year, flat at every covered dose, read on the provider's own plan page.
Is compounded semaglutide FDA-approved?
No. Compounded preparations are not FDA-approved finished products, and no trial figure transfers to them.
Related on this site
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- FDA Compounded GLP-1 Rules in 2026Journal
- Tirzepatide Telehealth in ArizonaStates
- Tirzepatide Telehealth in AlaskaStates
- Tirzepatide Telehealth in AlabamaStates
- Medical and Regulatory DisclaimerCore & Trust
- Tirzepatide Telehealth in WyomingStates
- Tirzepatide Telehealth in WisconsinStates
Related coverage
Semaglutide Ranked. “Best Compounded Semaglutide 2026: Ranked on Six Checkable Tests.” S.J Partners LLC, 2026-07-26. https://semaglutideranked.com/best-compounded-semaglutide-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.